PodClips Logo

When patients have heart failure with or without reduction in EF [ejection fraction], outcomes are better if they're taking SGLT-2 inhibitors, even if they are not patients with type 2 diabetes.
0:10
Peter Attia

SGL2-T Inhibitors Reduce Death Risk in Patients With Heart Failure

AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins

The Peter Attia Drive

Topic: moment

SGL2-T Inhibitors Reduce Death Risk in Patients With Heart Failure

SGL2-T Inhibitors Reduce Death Risk in Patients With Heart Failure

AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins - Peter Attia
0:00
2:40
left arrow
0:00
2:40
SGL2-T Inhibitors Reduce Death Risk in Patients With Heart Failure
AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins
AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins - Peter Attia
9 of 13
right arrow
AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins - Peter Attia
left arrow
right arrow
1
+
1.0
-
+
1.0
-
0
ms